1Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-607.
2Wyne KL (2003) Free fatty acids and type 2 diabetes mellitus. Am J Med 115: 29S-36S.
3Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97: 2859-65.
4Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M (2001) Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-8.
5Berg AH, Scherer PE (2005)Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-49.
6Romero G, Luttrell L, Rogol A, Zeller K, Hewlett E, et al. (1988)Phosphatidylinositol-glycan anchors of membrane proteins: potential precursors of insulin mediators. Science 240: 509-11.
7Sun TH, Heimark DB, Nguygen T, Nadler JL, Larner J (2002)Both myo-inositol to chiro-inositol epimerase activities and chiroinositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 293: 1092-8.
8Field MC (1997)Is there evidence for phospho-oligosaccharides as insulin mediators? Glycobiology 7: 161-8.
9Pintaudi B, Di Vieste G, Bonomo M (2016) The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes. Int J Endocrinol 2016: 9132052.
10Carlomagno G, Nordio M, Chiu TT, Unfer V (2011) Contribution of myo-inositol and melatonin to human reproduction. Eur J Obstet Gynecol Reprod Biol 159: 267-72.
11 Unfer V, Carlomagno G, Dante G, Facchinetti F (2012) Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 28: 509-15.
12Saleem F, Rizvi SW (2017) New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus 9: e1844.
13 Santamaria A, Di Benedetto A, Petrella E, Pintaudi B, Corrado F, et al. (2016) Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med 29: 3234-7.
14D’Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, et al. (2015) Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Obstet Gynecol 126: 310-5.
15 Crawford TJ, Crowther CA, Alsweiler J, Brown J (2015) Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes. Cochrane Database of Syst Rev 12: CD0115077.
16D’Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, et al. (2013)Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care 36: 854-7.
17Corrado F, D’Anna R, di Vieste G, Giordano D, Pintaudi B, et al. (2011)The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diab Medicine 28: 972-5.
18 Lubin V, Shojai R, Darmon P, Cosson E (2016) A pilot study of gestational diabetes mellitus not controlled by diet alone: first-line medical treatment with myoinositol may limit the need for insulin. Diabetes Metab 42: 192-5.
19 Mancini M, Andreassi A, Salvioni M, Pelliccione F, Mantellassi G, et al. (2016) Myoinositol and D-Chiro Inositol in Improving Insulin Resistance in Obese Male Children: Preliminary Data. Int J Endocrinol 2016: 8720342.
20Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506.
21 De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, et al. (2011) Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor α gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J 25: 3695-707.
22 Ma X, Sun Z, Liu Y, Jia Y, Zhang B, et al. (2013) Resveratrol improves cognition and reduces oxidative stress in rats with vascular dementia. Neural Regen Res 8: 2050-9.
23Cao C, Lu R, Kivlin B, Wallin E, Card E, et al. (2009) SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes J Cell Mol Med 13(9B): 3632-43.
24Nichols JA, Katiyar SK (2010) Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms. Arch Dermatol Res 302: 71-83.
25Fisher GJ, Kang S, Varani J, Bata-Csorgo Z, Wan Y, et al. (2002) Mechanisms of photoaging and chronological skin aging. Arch Dermatol 138: 1462-70.
26 Stojanović S, Sprinz H, Brede O (2001) Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391: 79-89.
27 Yan F, Sun X, Xu C (2018)Protective effects of resveratrol improve cardiovascular function in rats with diabetes. Exp Ther Med 15: 1728-34.
28 Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al. (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-840.
29Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-82.
30Howells LM, Berry DP, Elliott PJ, Jacobson EW, Hoffmann E, et al. (2011) Phase I randomized double-blind pilot study of micronized resveratrol (SRT501)In patients with hepatic metastases-safety, pharmacokinetics and pharmacodynamics. Cancer Prev Res 4: 1419-25.
31Chan WK, Delucchi AB (2000) Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67: 3103-12.
32 Amri A, Chaumeil JC, Sfar S, Charrueau C (2012) Administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 158: 182-93.
33 Malvasi A, Kosmas I, Mynbaev OA, Sparic R, Gustapane S, et al. (2017) Can trans resveratrol plus d-chiro-inositol and myo-inositol improve maternal metabolic profile in overweight pregnant patients? Clin Ter 168: e240-7.
34 Green S (1991) How many subjects does it take to do a regression analysis. Multivar Behav Res 26: 499-510.
35WHO (2019) Obesity and overweight. WHO definition, Switzerland.
36Professional Practice Committee: Standards of Medical Care in Diabetes-2018. Diabetes Care 41(Supplement 1): S3.
37Vitturi N, Soattin M, De Stefano F, Vianello D, Zambon A, et al. (2015) Ultrasound, anthropometry and bioimpedance: a comparison in predicting fat deposition in non-alcoholic fatty liver disease. Eat Weight Disord 20: 241-7.
38 Guarino G, Ragozzino G, Della Corte T, Fontana S, Strollo F, et al. (2018) Selenium Supplementation in Obese Patients with Subclinical Hypothyroidism and Type 2 Diabetes. J Nutr Health Sci 5: 202.
39Giampaoli S, Palmieri L, Donfrancesco C, Lo Noce C, Pilotto L, et al. (2015) Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 1998-2012. Eur J Prev Cardiol 22(2 Suppl): 9-37.
40Giampaoli S, Palmieri L, Panico S, Vanuzzo D, Ferrario M, et al. (2006) Favorable cardiovascular risk profile (Low Risk) and 10-year stroke incidence in women and men: Findings on 12 Italian population samples. Am J Epidemiol 163: 893-902.
41 Palmieri L, Donfrancesco C, Giampaoli S, Trojani M, Panico S, et al. (2006) Favorable cardiovascular risk profile and 10-year coronary heart disease incidence in women and men: Results from the Progetto CUORE. Eur J Cardiovasc Prev Rehabil 13: 562-70.
42 Fischer-Posovszky P, Kukulus V, Tews D, Unterkircher T, Debatin KM, et al. (2010) Resveratrol regulates human adipocyte number and function in a Sirt1- dependent manner. Am J Clin Nutr 92: 5-15.
43Vang O, Ahmad N, Baile CA, Baur JA, Brown K, et al. (2011) What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 6: e19881.
44 Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, et al. (2011) Clinical trials of resveratrol. Ann N Y Acad Sci 1215: 161-9.
45Poulsen MM, Jørgensen JO, Jessen N, Richelsen B, Pedersen SB (2013)Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann N Y Acad Sci 1290: 74-82.
46Tomé-Carneiro J, Gonzálvez M, Larrosa M, Yáñez-Gascón MJ, García-Almagro FJ, et al. (2012) One-year consumption of a grape nutraceutical containing resveratrol im’proves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 110: 356-63.
47 pringer M, Moco S (2019) Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. Nutrients 11: E143.
48 Pan MH, Wu JC, Ho CT, Lai CS (2018) Antiobesity molecular mechanisms of action: Resveratrol and pterostilbene. Biofactors 44: 50-60.
49 Borghi C, Rodriguez-Artalejo F, De Backer G, Dallongeville J, Medina J, et al. (2018) Serum uric acid levels are associated with cardiovascular risk score: A post hoc analysis of the EURIKA study. Int J Cardiol 253: 167-73.
50 Carluccio E, Coiro S, Ambrosio G (2018) Unraveling the relationship between serum uric acid levels and cardiovascular risk. Int J Cardiol 253:174-5.
51 Zheng BK, Li N (2018) Association of serum uric acid levels and cardiovascular risk score. Int J Cardiol 258: 297.
52 Sun GZ, Wang HY, Chen YT, Sun YX (2018) Serum uric acid levels positively correlates with 10-year cardiovascular risk score in the general population from China. Int J Cardiol 266: 259.
53 Borghi C (2018) Gout and CV disease: It is time to move on. Int J Cardiol 270: 311.
54 Calvo Aranda E, Andres M, Gonzalez Martin J, Abdelkader Abu-Sneimeh A, Carrion O, et al. (2018) Urate crystals and inflammation. Cardiovascular impact of gout. Int J Cardiol 271: 295.
55 Mazidi M, Katsiki N, Mikhailidis DP, Banach M (2019) Association of ideal cardiovascular health metrics with serum uric acid, inflammation and atherogenic index of plasma: A population-based survey. Atherosclerosis 284: 44-9.
56 Koushki M, Dashatan NA, Meshkani R (2018) Effect of Resveratrol Supplementation on Inflammatory Markers: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Ther 40: 1180-92.